Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dosing with ropinirole in a clinical setting.

A D Korczyn1, C Thalamas, C H Adler

  • 1Sieratzki Chair of Neurology, Tel Aviv University, Tel Aviv, Israel. neuro13@ccsg.tau.ac.il

Acta Neurologica Scandinavica
|September 13, 2002
PubMed
Summary

Optimal ropinirole (ReQuip) dosage for early Parkinson's disease (PD) may exceed 7.5 mg/day. Continued dose titration benefits most patients, with some requiring up to 24 mg/day for therapeutic response.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pseudo-anticipation in Creutzfeldt-Jakob disease is due to a rhomboid-shaped artifact.

European journal of neurology·2019
Same author

Clinical and radiological determinants of transient symptoms associated with infarction (TSI).

Journal of the neurological sciences·2018
Same author

High hair cortisol concentrations predict worse cognitive outcome after stroke: Results from the TABASCO prospective cohort study.

Psychoneuroendocrinology·2017
Same author

Gait instability in valproate-treated patients: Call to measure ammonia levels.

Acta neurologica Scandinavica·2017
Same author

Quality-of-life perception by Parkinson's disease patients and caregivers.

Acta neurologica Scandinavica·2017
Same author

The effect of schooling on reported age of onset of cognitive decline: A collaborative study.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2016

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Parkinson's disease (PD) is a progressive neurodegenerative disorder.
  • Ropinirole (ReQuip) is a dopamine agonist used for PD treatment.

Purpose of the Study:

  • To determine the optimal dose of ropinirole for early Parkinson's disease (PD).

Main Methods:

  • Analysis of six-month data from three monotherapy trials in PD patients.
  • Evaluation of dose titration effects on therapeutic response.

Main Results:

  • 75% of patients achieved a therapeutic response at or below 7.5 mg/day.
  • Higher dose increases (mean 14.8 mg/day) correlated with greater improvements (17.4%) compared to smaller increases (mean 3.4 mg/day, 10.8%).
  • Mean ropinirole doses increased over 3- and 5-year trials, reaching 10.4-14.9 mg/day.

Related Experiment Videos

Conclusions:

  • While a therapeutic response to ropinirole is often seen at or below 7.5 mg/day, continued dose titration is beneficial for most early PD patients.
  • Some patients may require the maximum recommended dose of 24 mg/day for optimal treatment.
  • Individualized dose titration is crucial for managing early Parkinson's disease with ropinirole.